The move ends a turbulent saga for AstraZeneca, which successfully developed a coronavirus shot but struggled to sell it amid competition and the emergence of rare but serious side effects.
The deal with Metaphore Biotechnologies is the third to emerge from a Flagship alliance that’s meant to boost the Danish drugmaker’s pipeline of weight loss medicines.
Some results have been hidden because they may be inaccessible to you